This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Wall Street Analysts Think Annovis Bio, Inc. (ANVS) Could Surge 190.96%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 191% upside potential for Annovis Bio, Inc. (ANVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
New Strong Buy Stocks for April 18th
by Zacks Equity Research
EGY, ANVS, HCC, MPC and ANDE have been added to the Zacks Rank #1 (Strong Buy) List on April 18, 2023.
Annovis Bio, Inc. (ANVS) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Annovis Bio, Inc. (ANVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Avidity (RNA) Down on Update From Neuromuscular Disease Study
by Zacks Equity Research
Avidity Biosciences (RNA) provides an update on its phase I/II study of its lead product candidate AOC 1001 for the treatment of myotonic dystrophy type I. The stock falls about 17%.
Here's Why Momentum in Annovis Bio, Inc. (ANVS) Should Keep going
by Zacks Equity Research
Annovis Bio, Inc. (ANVS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up
by Zacks Equity Research
Intra-Cellular Therapeutics (ITCI) announces positive top-line data from its phase III study evaluating lumateperone for the treatment of depression. Stock surges 16% following the news.
Bicycle (BCYC) up on Collaboration With Novartis for Conjugates
by Zacks Equity Research
Bicycle (BCYC) and Novartis enter into a collaboration agreement to develop, manufacture and commercialize conjugate drugs for several oncology indications. Stock soars following the news.
Vertex (VRTX) Inks Licensing Deal With CRISPR for Diabetes Drug
by Zacks Equity Research
Vertex Therapeutics (VRTX) enters into a licensing agreement with CRISPR for the latter's gene-editing technology to accelerate the development of its type I diabetes hypoimmune therapy programs.
Are Medical Stocks Lagging Annovis Bio (ANVS) This Year?
by Zacks Equity Research
Here is how Annovis Bio, Inc. (ANVS) and Aptose Biosciences (APTO) have performed compared to their sector so far this year.
Pharming (PHAR) Rare Disease Drug Joenja Gets FDA Nod, Stock Up
by Zacks Equity Research
Pharming Group (PHAR) obtains FDA approval for leniolisib for the treatment of a rare pediatric disease. The stock of the company is up about 33% following the same.
COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar
by Zacks Equity Research
COYA and Dr. Reddy's enter into a license agreement where the latter will source proposed biosimilar of abatacept biosimilar to Coya to develop and commercialize COYA 302.
Nurix's (NRIX) Stock Up Due to License Option Exercise by Gilead
by Zacks Equity Research
Nurix Therapeutics (NRIX) to earn an option fee of $20 million as partner Gilead exercised its option to exclusively license Nurix's investigational targeted protein degrader molecule NX 0479.
Deciphera (DCPH) Gets Breakthrough Tag for Qinlock Expanded Use
by Zacks Equity Research
The FDA grants breakthrough tag to Qinlock for treating second-line GIST patients with mutations in KIT Exon 11 and 17/18. Stock up on Tuesday in response.
Mirum's (MIRM) Livmarli Gets FDA Nod for Expanded Use, Stock Up
by Zacks Equity Research
Mirum Pharmaceuticals (MIRM) announces FDA approval of Livmarli for infants 3 months and older. Stock up 6% in response to the news.
Seagen (SGEN) Set to be Acquired by Pfizer for $43 B, Stock Up
by Zacks Equity Research
Seagen is set to be acquired by the large-cap pharma company, Pfizer, at a valuation of $43 billion. The stock is up about 15% in response to the news.
Acadia (ACAD) Gets FDA Approval for Daybue for Rett Syndrome
by Zacks Equity Research
Acadia Therapeutics (ACAD) announces the FDA approval of its Rett Syndrome drug, trofinetide, for the treatment of adult and pediatric patients two years of age and older. Going to be marketed as Daybue in the United States.
Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Amphastar Pharmaceuticals (AMPH) and Annovis Bio, Inc. (ANVS) have performed compared to their sector so far this year.
Wall Street Analysts Believe Annovis Bio, Inc. (ANVS) Could Rally 152.89%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 152.9% upside potential for Annovis Bio, Inc. (ANVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is Annovis Bio (ANVS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Annovis Bio, Inc. (ANVS) and BioLife Solutions, Inc. (BLFS) have performed compared to their sector so far this year.
Does Annovis Bio, Inc. (ANVS) Have the Potential to Rally 178.45% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Annovis Bio, Inc. (ANVS) points to a 178.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Are Medical Stocks Lagging McKesson (MCK) This Year?
by Zacks Equity Research
Here is how McKesson (MCK) and Annovis Bio, Inc. (ANVS) have performed compared to their sector so far this year.
Can Annovis Bio, Inc. (ANVS) Climb 251% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 251.4% in Annovis Bio, Inc. (ANVS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Believe Annovis Bio, Inc. (ANVS) Could Rally 239%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Annovis Bio, Inc. (ANVS) points to a 239.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Annovis (ANVS) Gains on FDA Authorization for AD Study
by Zacks Equity Research
Annovis (ANVS) shares jump following the FDA's authorization to proceed with the phase II/III clinical study of lead candidate buntanetap in moderate Alzheimer's Disease (AD).
Annovis Bio (ANVS) Begins Dosing in Phase III Parkinson's Study
by Zacks Equity Research
Annovis Bio (ANVS) doses first patient in the phase III study evaluating buntanetap in early Parkinson's Disease. Stock surges.